EP0262119A1 - Procede de detection de facteur de determination precoce de grossesse (epf) ches des mammiferes, procedes de purification d'epf et de production d'anticorps monoclonaux - Google Patents

Procede de detection de facteur de determination precoce de grossesse (epf) ches des mammiferes, procedes de purification d'epf et de production d'anticorps monoclonaux

Info

Publication number
EP0262119A1
EP0262119A1 EP86901744A EP86901744A EP0262119A1 EP 0262119 A1 EP0262119 A1 EP 0262119A1 EP 86901744 A EP86901744 A EP 86901744A EP 86901744 A EP86901744 A EP 86901744A EP 0262119 A1 EP0262119 A1 EP 0262119A1
Authority
EP
European Patent Office
Prior art keywords
epf
antibody
cells
serum
urine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP86901744A
Other languages
German (de)
English (en)
Other versions
EP0262119A4 (fr
Inventor
Halle Morton
Alice Christina Cavanagh
Barbara Ellen Rolfe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Queensland UQ
Original Assignee
University of Queensland UQ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Queensland UQ filed Critical University of Queensland UQ
Publication of EP0262119A4 publication Critical patent/EP0262119A4/fr
Publication of EP0262119A1 publication Critical patent/EP0262119A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4715—Pregnancy proteins, e.g. placenta proteins, alpha-feto-protein, pregnancy specific beta glycoprotein

Definitions

  • This invention relates to a method for detecting early pregnancy factor (EPF) in mammals, purifying EPF and a method for producing a monoclonal antibody therefor.
  • Pregnancy involves two early important milestones - fertilization of the ovum and implantation of the fertilized ovum in the uterus approximately eight-ten days after fertilization.
  • the present invention resides in a method for producing EPF from any mammalian cell source including the steps of: growing a selected cell which produces EPF in a culture medium to produce a supernatant medium containing EPF and other products; and harvesting the supernatant medium to obtain the EPF.
  • the present invention resides in a method for purifying EPF including the steps of: passing a supernatant medium containing EPF through a column containing a selective absorbent for the EPF (i.e. immuno absorption of the EPF); eluting the EPF from the selective absorbent to produce a first eluate; effecting reversed phase high performance liquid chromotography (HPLC) on the first eluate in a column; and eluting the bound EPF from the column to collect the purified EPF.
  • a selective absorbent for the EPF i.e. immuno absorption of the EPF
  • HPLC reversed phase high performance liquid chromotography
  • the first eluate is dialysed against a buffer solution to remove any small molecular weight products; the dialysis product is concentrated; gel filtration is effected on the concentrate; and selected fractions of the filtrate are collected and the reversed phase high performance chromotography is effected on the collected fractions.
  • the present invention resides in a method for producing monoclonal antibodies to EPF including the steps of: immunizing an animal with purified EPF; removing the spleen of the animal and fusing the spleen cells with selected cells; growing the fused cells in a culture medium; selecting the hybrid (fused) cells from the non-fused cells; and cloning out the hybrid cells producing the EPF antibody by limiting dilution methods.
  • the hybrid cells may be grown in a culture medium (i.e. in vitro) to produce high concentrations of monoclonal antibody to EPF, or in BALB/C mice (i.e. in vivo) and harvesting from these mice serum and/or ascites which will contain high concentrations of monoclonal antibody to EPF.
  • the present invention resides in a method for pregnancy diagnosis in a female mammal including the steps of: mixing EPF antibodies with serum or urine believed to contain EPF; and monitoring any reaction due to the presence of EPF in the serum or urine.
  • Human EPF was produced by continuously growing Choriocarcinoma cells (sold under the trade mark "Be Wo” by the American Type Culture Collection, 12301 Parklawn Drive, Rockville, Maryland 20852 U.S.A. and deposited under ATCC Deposit No. CCL98), human myeloma cells (ATCC Deposit No. CCL 155) or human lymphoblastic leukemia cells (ATCC Deposit No. CRL 1582) in culture medium comprising "DMEM” ( "Dulbecco's Modification of Eagle's Medium”) (sold by Flow Laboratories Inc., 7655 Old Springhouse Road, McLean, VA 22102, U.S.A. and subsidiary companies in. inter alia Australia, Canada, Japan, the United Kingdom and Sweden), and foetal calf serum (sold by Commonwealth Serum Laboratories, Melbourne, Australia) and harvesting the supernatant medium. This supernatant medium contains human EPF and other products.
  • DMEM "Dulbecco's Modification of Eagle's Medium”
  • An immuno-absorption column is prepared using goat/anti-mouse EPF (or any other suitable EPF e.g. using rabbits or donkeys as the host for mouse, human or rat EPF).
  • anti-EPF IgG immunoglobulin
  • human serum and with foetal calf serum bound to cyanogen bromide activated Sepharose 4B (sold under the trade name
  • the supernatant medium, containing the EPF, is pumped through the column and the human EPF will bind to the anti-mouse EPF in the absorption column, the latter acting as a selective absorber of the human EPF.
  • the human EPF is eluted with 1M acetic acid/ 0.9% NaC1/10% dioxane and the eluate is dialysed and the buffer is exchanged for 1M acetic acid adjusted to pH3.0 by ammonium hydroxide to remove small molecular weight products. (All percentages are expressed as "%(w/v) or (v/v)").
  • the product is concentrated to a 3mL. volume and undergoes gel filtration in a column of Sephacryl S-200 (supplied by Pharmacia Biotechnology Products, Sweden - see page 84 of their"Catalogue 86")which has been equilibrated with 1M acetic acid adjusted to pH3.0 with ammonium hydroxide.
  • This sample is filtered on the basis of molecular size and, on a 16mm. x 900mm. column, collecting 2mL. fractions, fractions 60-80 (i.e. 120-160mL. flow) contain the EPF. These are pooled and TFA (trifluroacetic acid) added to a final concentration of 0.1%.
  • TFA trifluroacetic acid
  • the mixture is applied to a Beckman RPSC ultrapore reversed phase HPLC column (e.g. 4.6mm. x 75mm.) which has been equilibrated with 0.1% TFA.
  • a Beckman RPSC ultrapore reversed phase HPLC column e.g. 4.6mm. x 75mm.
  • the bound EPF is eluted with a 2 minute linear gradient to 25% isopropanol followed by a 30 minute linear gradient to 30% isopropanol both containing 0.1% TFA at a flow rate of 1mL. /minute.
  • the fractions eluted with retention times between 9.8 - 11.3 minutes contain the purified EPF. These fractions are pooled and stored. With some immunoabsorbents, it is possible to omit the dialysis and gel filtration steps and apply the eluate directly to the reversed phase HPLC column (which has been equilibrated with 0.1% TFA), after addition of TFA to a final concentration of 0.1%.
  • BALB/c mice e.g.
  • mice bred from BALB/cJ strain mice from The Jackson Laboratory, Bar Harbor, Maine, 04609, U.S.A.
  • EPF purified EPF
  • the spleens were removed and the spleen cells were fused with mouse myeloma cells (e.g. catalogue Nos. X63-Ag8-653 or Sp2/0-Ag-l4 from Flow Laboratories Australasia Pty. Ltd., 140 Wicks Road, North Ryde, Sydney, N.S.W. 2113, Australia).
  • the cells are grown in "DMEM" medium with 2mM fresh L-glutamine,20% foetal calf serum plus antibiotics and fungicides, and the hybrid cells selected by addition of HAT medium (containing
  • the hybrid cells are cloned out by limiting dilution techniques and are tested to establish which clones produce an antibody to EPF.
  • the hybrid cells may be grown in a culture medium (i.e. in vitro) to produce high concentrations of monoclonal antibody to EPF, or in BALB/c mice (i.e. in vivo) and harvesting from these mice serum and/or ascites which will contain high concentrations of monoclonal antibody to EPF. Those cells are recloned until a cell producing a monoclonal antibody is achieved. Samples of clones in intermediate or final stages are stored in liquid N 2 .
  • the resultant product can be used to detect EPF in human serum or urine for pregnancy diagnosis.
  • EPF including some labelled with [ 125 I] is mixed with anti-EPF antibody and the mixture is allowed to react to produce a complex.
  • the complex is precipitated by adding a precipitating antibody or polyethylene glycol.
  • a negative sample i.e. no EPF in the serum
  • a positive sample containing EPF
  • the labelled EPF and the antibody will result in a low ⁇ count. This is due to competitive binding between the EPF and labelled EPF with the antibody, as the EPF will prevent the labelled EPF from binding.
  • two different antibodies to EPF may be used, the antibodies binding to different sites on the EPF molecule.
  • One antibody is placed in a plastic tube or on polystyrene beads or sticks and allowed to bind.
  • the serum is added to the tube or placed in contact with the beads or sticks and EPF therein is allowed to bind with the first antibody.
  • a second antibody, labelled with Iodine 125, is then allowed to bind with EPF.
  • the bound Iodine 125 is counted with a ⁇ -counter and a high count indicates the presence of EPF.
  • This method would be particularly suitable for a home pregnancy testing kit where the first antibody is bound on a testing stick which is dipped into the female's urine specimen and then into a first container supplied with the kit containing the second antibody labelled with an enzyme which undergoes a colour change when the stick dipped into a second container supplied with the kit containing a suitable substrate.
  • the embodiments described above are specific and that a range of chemical proportions and times may be used.
  • the gel filtration may be carried out using "Sephadex G-100" (see page 80 of the Pharmacia Biotechnology Products "Catalogue 86”) equilibrated with 1M acetic acid pH2.5.
  • the methods are suitable for the EPF of all mammalian animals.
  • the method for detecting pregnancy can be extremely important in the horse and cattle industries and in the preservation of endangered species.
  • the giant panda gives no indication of pregnancy but pregnancy could be determined, with out handling the female, by collecting urine e.g. from the cage floor, and assaying with the particular suitable monoclonal antibody.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Des cellules produisant de l'EPF sont cultivées dans un milieu de culture afin de produire un milieu surnageant contenant de l'EPF. Pour purifier l'EPF, celui-ci est absorbé par un absorbant sélectif dans une colonne, dialysé dans une solution tampon, concentré et filtré à travers un gel. Des parties sélectionées du filtrat sont soumises à une chromatographie liquide à phase inversée de haute performance, et l'EPF purifié est obtenu par élution de la colonne chromatographique. Il est possible de produire des anticorps monoclonaux de l'EPF pour détecter la présence d'EPF dans du sérum et fournir un moyen de détection de la grossesse ches des mammifères du sexe féminin.
EP86901744A 1985-03-12 1986-03-12 Procede de detection de facteur de determination precoce de grossesse (epf) ches des mammiferes, procedes de purification d'epf et de production d'anticorps monoclonaux Withdrawn EP0262119A1 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
AUPG966485 1985-03-12
AU9664/85 1985-03-12
AU9750/85 1985-03-15
AUPG975085 1985-03-15
AUPH240285 1985-09-12
AU2402/85 1985-09-12

Publications (2)

Publication Number Publication Date
EP0262119A4 EP0262119A4 (fr) 1988-02-08
EP0262119A1 true EP0262119A1 (fr) 1988-04-06

Family

ID=27157241

Family Applications (1)

Application Number Title Priority Date Filing Date
EP86901744A Withdrawn EP0262119A1 (fr) 1985-03-12 1986-03-12 Procede de detection de facteur de determination precoce de grossesse (epf) ches des mammiferes, procedes de purification d'epf et de production d'anticorps monoclonaux

Country Status (3)

Country Link
EP (1) EP0262119A1 (fr)
GB (1) GB2192634B (fr)
WO (1) WO1986005498A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3603053A1 (de) * 1986-01-30 1987-08-06 Schering Ag Schwangerschaftsnachweis mit epf
EP0345260A4 (fr) * 1986-12-22 1990-05-14 Univ Queensland Procede de traitement des mammiferes utilisant des anticorps contre le facteur de grossesse precoce (epf).
NZ276670A (en) 1993-11-30 1998-01-26 Univ Queensland A method for the detection of heat shock protein cpn-10
US7034120B2 (en) 1999-02-02 2006-04-25 Edp Biotech Corporation, Inc. Method and apparatus for detecting conception in animals
AU2579599A (en) * 1998-02-02 1999-08-16 Concepto Diagnostics, Inc. Method and apparatus for detecting conception in animals
AU3511900A (en) * 1999-03-02 2000-09-21 Kems Bio-Test Ltd. Bovine pregnancy testing
CN108314732A (zh) * 2018-01-15 2018-07-24 妊达（北京）生物技术有限公司 一种抗牛早孕因子单克隆抗体细胞株单克隆抗体的制备方法
CN114894911B (zh) * 2022-03-18 2023-10-24 辽宁成大生物股份有限公司 一种控制牛血清产品质量方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL48741A (en) * 1975-12-26 1979-07-25 Rafa Labor Ltd Method for the determination of pregnancy

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, vol. 105, no. 13, 29th September 1986, page 170, abstract no. 109441g, Columbus, Ohio, US; A.C. CAVANAGH: "Purification and partial characterization of EPF", & REPROD. PERINAT. MED. 1985, 1 (EARLY PREGNANCY FACTORS), 179-89 *
CHEMICAL ABSTRACTS, vol. 105, no. 13, 29th September 1986, page 473, abstract no. 112770u, Columbus, Ohio, US; T.K. ROBERTS et al.: "Early pregnancy factor of human urine", & REPROD. PERINAT. MED. 1985, 1 (EARLY PREGNANCY FACTORS), 191-3 *
CHEMICAL ABSTRACTS, vol. 105, no. 13, 29th September 1986, page 489, abstract 112890h, Columbus, Ohio, US; H. MORTON: "EPF as a pregnancy protein", & REPROD. PERINAT. MED. 1985, 1 (EARLY PREGNANCY FACTORS), 53-64 *
CHEMICAL ABSTRACTS, vol. 105, no. 13, 29th September 1986, page 85, abstract no. 108668z, Columbus, Ohio, US; M. MESROGLI et al.: EPF as a marker for fertilization and implantation in the human", & REPROD. PERINAT. MED. 1985, 1 (EARLY PREGNANCY FACTORS), 233-5 *
See also references of WO8605498A1 *

Also Published As

Publication number Publication date
GB8720636D0 (en) 1987-10-07
EP0262119A4 (fr) 1988-02-08
GB2192634A (fr) 1988-01-20
WO1986005498A1 (fr) 1986-09-25
GB2192634B (en) 1990-03-21

Similar Documents

Publication Publication Date Title
Lindstrom et al. [29] Production and assay of antibodies to acetylcholine receptors
Goding Use of staphylococcal protein A as an immunological reagent
US4578335A (en) Interleukin 2 receptor
US4423147A (en) Monoclonal antibody to interferon-α
CA1247539A (fr) Methode pour detecter les complexes immuns dans le serum
JP2617289B2 (ja) モノクローナル抗体生産性ハイブリドマ細胞系
Bazin et al. Rat monoclonal antibodies. II. A rapid and efficient method of purification from ascitic fluid or serum
JPS63157977A (ja) ヒト腫瘍壊死因子に対するモノクローナル抗体を含有する敗血症治療薬及びリューマチ性疾患治療薬
CA1290266C (fr) Anticorps monoclonaux contre des proteines non reduites et non glycosylees parun enzyme
US4784942A (en) Monoclonal antibodies against autoimmune RNA proteins
CN105838679A (zh) 牛妊娠相关糖蛋白pag特异性单克隆抗体细胞株及其应用
EP0262119A1 (fr) Procede de detection de facteur de determination precoce de grossesse (epf) ches des mammiferes, procedes de purification d'epf et de production d'anticorps monoclonaux
JPH0611235B2 (ja) モノクロ−ナル抗体
Harford et al. Immunological approaches to the study of membrane receptors. A monoclonal antibody that inhibits the binding of asialoglycoproteins to the rat liver receptor.
US4299814A (en) Radioimmunoassay of MIF
NO303693B1 (no) Rent humant korboksyterminalt propeptid av type I prokollagen, antistoff og anvendelse av antistoff fremstilt mot dette, samt analysesett som omfatter antistoffet
EP0506523A2 (fr) Anticorps monoclonaux
Stenman et al. Characterization of a monoclonal antibody to human alpha-fetoprotein and its use in affinity chromatography
AU599021B2 (en) Method for detecting early pregnancy factor (epf) in mammals,purifying epf and method for producing a monoclonal antibody
US5264351A (en) Monoclonal antibodies against autoimmune RNA proteins
US4803167A (en) Monoclonal antidigoxtin antibodies
JPS6070360A (ja) 抗特異タイプの標識付モノクロ−ナル抗体を用いる受容体測定法
DE68917797T2 (de) Gegen menschliches Fibrinopepid A spezifische monoklonale Antikörper.
EP0084344A2 (fr) Anticorps monoclonaux anti-urokinase et leur procédé de préparation
CN115677851B (zh) 一种免疫阻断抗体或其抗原结合片段及其应用

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19870921

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR IT LI NL SE

17Q First examination report despatched

Effective date: 19900928

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19920714

RIN1 Information on inventor provided before grant (corrected)

Inventor name: CAVANAGH, ALICE, CHRISTINA

Inventor name: MORTON, HALLE

Inventor name: ROLFE, BARBARA, ELLEN